Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
Takehiro NakaiSho FukuiGenki KidoguchiYukihiko IkedaAyako KitadaAtsushi NomuraHiromichi TamakiMitsumasa KishimotoMasato OkadaPublished in: Clinical rheumatology (2022)
In most patients with SLE, B-T combination therapy is well tolerated with a good efficacy profile and glucocorticoid-reducing effect. Thus, B-T combination therapy represents a feasible option for patients with refractory lupus. Key Points • The safety and effectiveness of belimumab-calcineurin inhibitor combination therapy have not been addressed. • The drug retention rate of belimumab-tacrolimus combination therapy was over 90% at week 52 and around 80% on day 1000 • Almost none of the patients suffered from severe infection after the initiation of belimumab-tacrolimus combination therapy. • Belimumab-tacrolimus combination therapy is efficacious in suppressing lupus activity and achieving LLDAS.
Keyphrases
- combination therapy
- systemic lupus erythematosus
- disease activity
- end stage renal disease
- chronic kidney disease
- systematic review
- randomized controlled trial
- ejection fraction
- prognostic factors
- clinical trial
- emergency department
- rheumatoid arthritis
- signaling pathway
- patient reported outcomes
- peritoneal dialysis
- drug induced